（编辑 袁冠琳） 证券日报网讯 众生药业8月22日在互动平台回答投资者提问时表示，RAY0221是公司自主研发的一款具 有GLP-1/GIP/GCG三靶点活性的多肽药物，临床上拟用于治疗糖尿病、减肥及非酒精性脂肪肝，目前该 项目处于临床前研究阶段，后续将按计划有序推进项目开发工作。 ...

Core Viewpoint - The company, Saintno Biopharmaceuticals (688117), reported a mixed financial performance for 2024 and the first quarter of 2025, with significant growth in Q1 2025 driven by increased sales of specific products, while facing challenges in overall profitability due to rising R&D costs [2][6]. Financial Performance - In 2024, the company achieved operating revenue of 456.07 million yuan, a year-on-year increase of 4.84% [2] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was 45.61 million yuan, a decrease of 24.24% year-on-year [2] - For Q1 2025, the company reported operating revenue of 184.34 million yuan, a significant year-on-year increase of 77.15% [2] - The net profit attributable to the parent company for Q1 2025 was 47.12 million yuan, reflecting a year-on-year increase of 186.06% [2] R&D Progress - The company has made advancements in several R&D projects, including the approval of various raw materials and the establishment of a joint research center with Zhejiang University [3][6] - In 2024, the company invested 50.46 million yuan in R&D, representing 11.06% of its operating revenue, which is a 45.05% increase compared to the previous year [2] Overseas Market Strategy - The company plans to enhance its overseas sales strategy by building a professional sales and marketing team to improve market expansion and brand development [4] - An investment agreement was signed with Africa Bio Chem Co. Ltd in Tanzania for 30 million yuan, acquiring a 22.78% stake to strengthen its overseas presence [4] Capacity Expansion - The company is actively advancing several capacity expansion projects, including a production line for polypeptide raw materials and a technology transformation project for formulations [5] - The production line project has entered the validation stage, and the company aims to meet the growing customer demand through these expansions [5] Market Sentiment - Recently, one institution has given a buy rating for the stock, indicating positive market sentiment [7] - The stock has seen a net inflow of 59.1 million yuan in financing over the past three months, suggesting increased investor interest [8]